COVEVOL: Natural Evolution at 6 Months of COVID-19.
anosmia
anxiety
asthenia
dyspnea
persistent symptoms
post-COVID-19
risk factors
“long COVID”
Journal
Viruses
ISSN: 1999-4915
Titre abrégé: Viruses
Pays: Switzerland
ID NLM: 101509722
Informations de publication
Date de publication:
25 10 2021
25 10 2021
Historique:
received:
28
07
2021
revised:
04
10
2021
accepted:
07
10
2021
entrez:
27
11
2021
pubmed:
28
11
2021
medline:
15
12
2021
Statut:
epublish
Résumé
Many studies have investigated post-COVID symptoms, but the predictors of symptom persistence remain unknown. The objective was to describe the natural course of the disease at 6 months and to identify possible factors favoring the resurgence or persistence of these symptoms. COVEVOL is a retrospective observational descriptive study of 74 patients. All patients with positive SARS-CoV-2 PCR from March 2020 were included. We compared a group with symptom persistence (PS group) with another group without symptom persistence (no-PS group). Fifty-three out of seventy-four patients (71.62%) described at least one persistent symptom at 6 months of SARS-CoV-2 infection. In the PS group, 56.6% were women and the average age was 54.7 years old [21-89.2] ± 16.9. The main symptoms were asthenia (56.6%,
Identifiants
pubmed: 34834958
pii: v13112151
doi: 10.3390/v13112151
pmc: PMC8619893
pii:
doi:
Types de publication
Journal Article
Observational Study
Langues
eng
Sous-ensembles de citation
IM
Références
J Med Virol. 2021 Feb;93(2):1013-1022
pubmed: 32729939
JAMA. 2020 Apr 28;323(16):1574-1581
pubmed: 32250385
Infection. 2020 Dec;48(6):965-967
pubmed: 32415334
Eur Arch Otorhinolaryngol. 2020 Aug;277(8):2251-2261
pubmed: 32253535
BMC Infect Dis. 2021 Mar 25;21(1):304
pubmed: 33765941
Clin Microbiol Infect. 2021 Jan;27(1):89-95
pubmed: 32979574
Eur Respir J. 2020 May 14;55(5):
pubmed: 32217650
Eur J Clin Microbiol Infect Dis. 2021 Nov;40(11):2421-2425
pubmed: 33893570
J Infect Dis. 2021 Feb 13;223(3):409-415
pubmed: 32692346
Microbes Infect. 2021 May-Jun;23(4-5):104803
pubmed: 33667643
J Adv Res. 2020 Mar 16;24:91-98
pubmed: 32257431
J Infect. 2021 Mar;82(3):378-383
pubmed: 33450302
Lancet. 2021 Jan 16;397(10270):220-232
pubmed: 33428867
Gut. 2020 Jun;69(6):1002-1009
pubmed: 32213556
Lancet Psychiatry. 2021 Feb;8(2):130-140
pubmed: 33181098
Bull Acad Natl Med. 2020 Oct;204(8):769
pubmed: 32836268
J Rehabil Med. 2020 May 25;52(5):jrm00063
pubmed: 32449782
J Intern Med. 2021 Aug;290(2):451-461
pubmed: 33403772
JAMA. 2020 Aug 11;324(6):603-605
pubmed: 32644129
Cureus. 2020 Oct 26;12(10):e11176
pubmed: 33262913
Front Hum Neurosci. 2021 Aug 11;15:666468
pubmed: 34456694
Rev Francoph Lab. 2020 Nov;2020(526):40-47
pubmed: 33163103
BMJ. 2020 May 22;369:m1966
pubmed: 32444366
JAMA. 2021 May 18;325(19):2015-2016
pubmed: 33825846
Lancet Infect Dis. 2020 Oct;20(10):1115-1117
pubmed: 32888409
J Infect. 2020 Dec;81(6):e4-e6
pubmed: 32853602
J Med Virol. 2021 Apr;93(4):1926-1928
pubmed: 33393696
Thorax. 2021 Dec;76(12):1242-1245
pubmed: 33927016
Clin Infect Dis. 2020 Nov 30;:
pubmed: 33252665
Int J Environ Res Public Health. 2020 Mar 06;17(5):
pubmed: 32155789
Proc Natl Acad Sci U S A. 2021 Feb 23;118(8):
pubmed: 33536313
Open Forum Infect Dis. 2021 Jan 29;8(4):ofab042
pubmed: 33875970
Virol Sin. 2020 Dec;35(6):833-837
pubmed: 32748131
ERJ Open Res. 2020 Oct 26;6(4):
pubmed: 33257910
Microorganisms. 2021 Aug 12;9(8):
pubmed: 34442798
Nat Med. 2021 Apr;27(4):601-615
pubmed: 33753937
J Infect. 2020 Aug;81(2):e72-e73
pubmed: 32389787
JAMA Otolaryngol Head Neck Surg. 2020 Jul 1;146(7):674-675
pubmed: 32267483
J Med Virol. 2021 Feb;93(2):1045-1056
pubmed: 32749705
MMWR Morb Mortal Wkly Rep. 2020 Jul 31;69(30):993-998
pubmed: 32730238